Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954565 | 1.00 | L3MBTL1 (0.52) | L3MBTL1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL11482231 | 1.00 | L3MBTL1 (0.52) | L3MBTL1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL8308938 | 0.87 | CYP17A1 (0.46) | L3MBTL1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL27974672 | 0.82 | L3MBTL1 (0.53) | L3MBTL1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL1253507 | 0.82 | L3MBTL1 (0.53) | L3MBTL1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL29103210 | 0.82 | KDM1A (0.51) | L3MBTL1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL12360950 | 0.81 | CA9 (0.52) | KDM4EALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL14298196 | 0.81 | CA9 (0.52) | KDM4EALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL15452358 | 0.80 | L3MBTL1 (0.52) | L3MBTL1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL5326497 | 0.78 | L3MBTL1 (0.50) | L3MBTL1KDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390413-B1 | ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10450335-B2 | Antiviral oxime phosphoramide compounds | MERCK SHARP & DOHME CORP. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180362563-A1 | ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3390413-A1 | ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106069-A1 | ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-7763623-B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2009012375-A2 | SQUARATE KINASE INHIBITORS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1976854-A2 | HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYYSLIPIDEMIA | Shering Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007087204-A2 | HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYYSLIPIDEMIA | SCHERING CORPOORATION (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION | 2007-07-26 | — | — | US | disclosed |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| EP-0507650-B1 | Piperidine derivatives, their preparation and their therapeutic application | SYNTHELABO (FR) | 1996-05-22 | — | — | EP | disclosed |
| US-5280030-A | Containing 1-benz(oxazole, thiazole or imidazole)-4-imidazole piperidine compound | SYNTHELABO (FR) | 1994-01-18 | — | — | US | disclosed |
| EP-0271798-B1 | O-SUBSTITUTED TETRAHYDROPYRIDINE OXIME CHOLINERGIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-04-07 | — | — | EP | disclosed |
| EP-0507650-A1 | Piperidine derivatives, their preparation and their therapeutic application | SYNTHELABO (FR) | 1992-10-07 | — | — | EP | disclosed |
| US-4786648-A | ANALGESIC | WARNER-LAMBERT COMPANY (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0271798-A2 | O-Substituted tetrahydropyridine oxime cholinergic agents | WARNER-LAMBERT COMPANY (US) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | GPR119, HCAR1, LDLR | L3MBTL1 4025/4885KDM4E 4538/4885ALDH1A1 2152/4885 |
| US-20180362563-A1 | ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS | TYMP, MTAP, PNP | L3MBTL1 3514/4885KDM4E 641/4885ALDH1A1 2355/4885 |
| US-10450335-B2 | Antiviral oxime phosphoramide compounds | TYMP, MTAP, POLR2E | L3MBTL1 3094/4885KDM4E 652/4885ALDH1A1 2251/4885 |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFB2, TGFBR1 | L3MBTL1 1656/4885KDM4E 2127/4885ALDH1A1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.